Literature DB >> 7287752

Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction.

S T Olson, K R Srinivasan, I Björk, J D Shore.   

Abstract

The kinetics of high affinity heparin binding to human antithrombin III has been studied by stopped flow fluorimetry, using the 40% antithrombin fluorescence enhancement resulting from this interaction. At mu 0.15, pH 7.4, and 25 degrees C, the observed pseudo-first order rate constant varies hyperbolically with heparin concentration with a limiting rate constant of 440 +/- 90 s-1, demonstrating that heparin binding is a two-step process involving a conformational change in antithrombin III. An identical dependence is produced when antithrombin is varied, consistent with a symmetrical mechanism in which heparin binding induces a conformational change in antithrombin rather than perturbing an equilibrium between two conformational states of the protein. The rate constant for dissociation of the antithrombin-heparin complex is 1.1-1.5 s-1 at mu 0.15, as determined from the ordinate intercept at low heparin concentrations or by dissociation of the antithrombin-heparin complex with iodide. Observation of a single pseudo-first order binding rates over a 400-fold heparin concentration range with no detectable lags is compatible with the initial binding step being in rapid equilibrium with a KD of 4.3 +/- 1.3 X 10(-5) M at mu 0.15. Variation in ionic strength primarily affects the KD for the initial binding step with little effect on the conformational change rate constants, implying that binding involves ionic interactions. Calculation of the overall dissociation equilibrium constant from these rate parameters agrees with the directly determined value of 7.2 +/- 1.9 X 10(-8) M at mu 0.15. A major function of the conformational change is, thus, to increase the affinity of heparin for antithrombin III greater than 300-fold. The implications of these findings for the mechanism of the heparin-catalyzed inhibition of coagulation proteases by antithrombin III are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7287752

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation.

Authors:  I Björk; K Ylinenjärvi; S T Olson; P Hermentin; H S Conradt; G Zettlmeissl
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

2.  Kinetic dissection of the pre-existing conformational equilibrium in the trypsin fold.

Authors:  Austin D Vogt; Pradipta Chakraborty; Enrico Di Cera
Journal:  J Biol Chem       Date:  2015-07-27       Impact factor: 5.157

3.  Discrimination between conformational selection and induced fit protein-ligand binding using Integrated Global Fit analysis.

Authors:  Franz-Josef Meyer-Almes
Journal:  Eur Biophys J       Date:  2015-11-04       Impact factor: 1.733

4.  Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Authors:  Benjamin Richard; Richard Swanson; Sophia Schedin-Weiss; Ben Ramirez; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

5.  The N-terminal segment of antithrombin acts as a steric gate for the binding of heparin.

Authors:  H L Fitton; R Skinner; T R Dafforn; L Jin; R N Pike
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

6.  Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.

Authors:  Nebojsa M Milovic; Jonathan R Behr; Michel Godin; Chih-Sheng Johnson Hou; Kristofor R Payer; Aarthi Chandrasekaran; Peter R Russo; Ram Sasisekharan; Scott R Manalis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

7.  A fragment of antithrombin that binds both heparin and thrombin.

Authors:  L Rosenfeld; I Danishefsky
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

8.  Arginine residues are critical for the heparin-cofactor activity of antithrombin III.

Authors:  A M Jorgensen; C L Borders; W W Fish
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

9.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  Cloning of the full-length cDNA of porcine antithrombin III and comparison with its human homolog.

Authors:  Younan Chen; Weidong Tan; Shengfang Qin; Jie Zhang; Hong Bu; Youping Li; Yanrong Lu; Jingqiu Cheng
Journal:  Comp Med       Date:  2009-08       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.